Quick Answer
Milestone Pharmaceuticals Inc. reported Research And Development Expense of $18.11 million for the year ending 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +26.1% in Research And Development Expense from 2024 to 2025.
- This data is from Milestone Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $3.09 million | Q2 2018: $2.55 million | Q3 2018: $3.91 million | Q1 2019: $7.77 million | Q2 2019: $10.53 million | Q3 2019: $9.55 million | Q1 2020: $11.87 million | Q2 2020: $8.62 million | Q3 2020: $8.23 million | Q1 2021: $8.60 million | Q2 2021: $9.43 million | Q3 2021: $9.73 million | Q1 2022: $8.77 million | Q2 2022: $10.66 million | Q3 2022: $9.83 million | Q1 2023: $10.26 million | Q2 2023: $8.62 million | Q3 2023: $6.72 million | Q1 2024: $3.64 million | Q2 2024: $2.82 million | Q3 2024: $3.96 million | Q1 2025: $4.98 million | Q2 2025: $3.67 million | Q3 2025: $3.94 million.
- Over the full 8 years of available data (2018 to 2025), Milestone Pharmaceuticals Inc.'s Research And Development Expense has grown by 7.5%.
- Historical annual values: Fiscal year 2025: $18.11 million | Fiscal year 2024: $14.36 million | Fiscal year 2023: $31.05 million | Fiscal year 2022: $39.83 million | Fiscal year 2021: $38.67 million | Fiscal year 2020: $34.49 million | Fiscal year 2019: $41.99 million | Fiscal year 2018: $16.85 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: